Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer
| Autor: | Lance K. Heilbrun, Susan Bolton, Daryn Smith, William M. Schopperle, Wael Sakr, Elisabeth I. Heath, Quratulain Ahmed, Yawen Ju |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male Pluripotent Stem Cells Cancer Research medicine.medical_treatment Sialoglycoproteins CD34 Article Embryonal carcinoma 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Medicine Humans Aged Retrospective Studies Prostatectomy Intraepithelial neoplasia business.industry Cancer Prostatic Neoplasms General Medicine Middle Aged medicine.disease Prognosis Up-Regulation Gene Expression Regulation Neoplastic 030104 developmental biology Oncology Podocalyxin chemistry 030220 oncology & carcinogenesis Antigens Surface Cancer research Immunohistochemistry Proteoglycans Neoplasm Grading business Biomarkers |
| Popis: | Background/aim Podocalyxin, a member of the CD34 family of cell surface sialomucins, is overexpressed in human embryonal carcinoma cell lines, as well as in several cancer types, and is associated with poor prognosis. Podocalyxin variants are associated with an increased risk and aggressiveness of prostate cancer. Herein podocalyxin protein expression in prostate cancer was characterized. Materials and methods Expression of podocalyxin as well as of TRA-1-60 and TRA-1-81 antigens was assessed immunohistochemically in 84 radical prostatectomy specimens and in adjacent normal tissues. Results Podocalyxin expression and H-scores were considerably higher in prostate tumors compared to normal tissues. High TRA-1-60 and TRA-1-81 staining was detected, however, in a much smaller percentage of prostate tumors, while their expression and H-scores were low in normal tissues. Similar trends for all three proteins were observed in prostatic intraepithelial neoplasia. Conclusion Overexpression of podocalyxin in prostate cancer renders the protein a putative immunohistochemical marker of prostate cancer that may contribute to stratification of patients for optimal treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|